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Abstract
Background: Refugees are at risk for poor outcomes from acute respiratory infections (ARI) because of
overcrowding, suboptimal living conditions, and malnutrition. We implemented surveillance for respiratory viruses
in Dadaab and Kakuma refugee camps in Kenya to characterize their role in the epidemiology of ARI among
refugees.
Methods: From 1 September 2007 through 31 August 2010, we obtained nasopharyngeal (NP) and oropharyngeal
(OP) specimens from patients with influenza-like illness (ILI) or severe acute respiratory infections (SARI) and tested
them by RT-PCR for adenovirus (AdV), respiratory syncytial virus (RSV), human metapneumovirus (hMPV),
parainfluenza viruses (PIV), and influenza A and B viruses. Definitions for ILI and SARI were adapted from those of
the World Health Organization. Proportions of cases associated with viral aetiology were calculated by camp and
by clinical case definition. In addition, for children < 5 years only, crude estimates of rates due to SARI per 1000
were obtained.
Results: We tested specimens from 1815 ILI and 4449 SARI patients (median age = 1 year). Proportion positive for
virus were AdV, 21.7%; RSV, 12.5%; hMPV, 5.7%; PIV, 9.4%; influenza A, 9.7%; and influenza B, 2.6%; 49.8% were
positive for at least one virus. The annual rate of SARI hospitalisation for 2007-2010 was 57 per 1000 children per
year. Virus-positive hospitalisation rates were 14 for AdV; 9 for RSV; 6 for PIV; 4 for hMPV; 5 for influenza A; and 1
for influenza B. The rate of SARI hospitalisation was highest in children < 1 year old (156 per 1000 child-years). The
ratio of rates for children < 1 year and 1 to < 5 years old was 3.7:1 for AdV, 5.5:1 for RSV, 4.4:1 for PIV, 5.1:1 for
hMPV, 3.2:1 for influenza A, and 2.2:1 for influenza B. While SARI hospitalisation rates peaked from November to
February in Dadaab, no distinct seasonality was observed in Kakuma.
Conclusions: Respiratory viral infections, particularly RSV and AdV, were associated with high rates of illness and
make up a substantial portion of respiratory infection in these two refugee settings.
Background
The World Health Organization (WHO) estimates that
acute lower respiratory infections (ALRI) cause nearly
four million deaths per year, a rate of more than 60
deaths/100,000 population [1]. Rates are even higher in
developing countries, where pneumonia is responsible
for an estimated 10-25% of all deaths among children
under 5 years of age [2]. While bacterial infections,
especially due to Streptococcus pneumoniae, are critically
important, viral causes are also associated with a sub-
stantial proportion of ALRI [3-7]. Viral infections can
exacerbate chronic or recurring respiratory conditions,
including asthma, thus representing an additional bur-
den of respiratory viruses [8,9].
Respiratory syncytial virus (RSV) and influenza viruses
are important pathogens in childhood pneumonia, and
primary infection with these two pathogens predisposes
children to secondary bacterial pneumonia, especially in
children < 2 years old [4,6,7,10,11]. RSV has been
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identified in 15-40% of cases in hospitalised children,
while human metapneumovirus (hMPV) and parain-
fluenza viruses (PIV) are associated with a substantial
proportion of ALRI in infants and young children;
asymptomatic infection with these pathogens appears
uncommon [4,6,7,12-14]. The United Nations High
Commissioner for Refugees (UNHCR) reports ALRI as
the leading cause of mortality and morbidity among
refugees in Kenya, where 30-40% of deaths of children <
5 years of age and up to 45% of morbidity is associated
with acute respiratory infections [1,15]. For viral respira-
tory pathogens, vaccines are currently available only to
prevent influenza; however, vaccine research and devel-
opment are focusing on many other leading viral patho-
gens [10,16-18]. Understanding the epidemiology of
specific aetiologies of ALRI in Africa is therefore impor-
tant if maximal benefit is to be obtained from new vac-
cine developments [19].
Displaced populations, including refugees, are at risk for
negative outcomes secondary to ALRI because of malnu-
trition, poor living conditions, and overcrowding
[12,20-22]. At the end of 2009, there were 15.2 million
refugees in the world, and some 5.2 million were in pro-
tracted situations [23]. Due to chronic intractable conflicts
in some parts of the world, many refugees live in long-
term camps for years or decades, with unique challenges
that are often as difficult as the crisis management neces-
sary during the emergency phase of refugee relief opera-
tions [24]. In some settings, additional challenges are
posed by sustained or intermittent bursts of large numbers
of new refugee arrivals from areas of renewed conflict [23].
In 2006, as the concern for human pandemic influenza
grew, the Kenya Ministry of Health, in collaboration
with the United States Centers for Disease Control and
Prevention (CDC), established a nationwide facility-
based influenza sentinel surveillance network comprising
11 sites, including Kakuma and Dadaab refugee camps
[25]. The objective was to characterize the epidemiology
of seasonal influenza and to detect novel influenza virus
strains. In 2007, we expanded testing at the two refugee
camps to include other respiratory viruses, with the aim
of determining a broader range of viral aetiologies of
acute respiratory infections (ARI). We present the
results of 3 years of this surveillance.
Methods
Site and population
From September 2007 to August 2010, surveillance was
conducted in Dadaab and Kakuma refugee camps,
located in east and northwest Kenya, respectively.
Dadaab is a large refugee camp complex and consists of
three camps–Hagadera, Ifo and Dagahaley. Each camp
has at least four health posts, which serve only outpati-
ents, and one hospital with both inpatient and
outpatient facilities. The refugee population in Dadaab
has grown by more than 150% since the onset of sur-
veillance, and as of August 2010, there were approxi-
mately 305,000 registered refugees. Kakuma had about
70,000 refugees throughout the study period and has
three outpatient clinics and one hospital. Health care
facilities in both camps serve the refugee population and
the local Kenyan population.
In each camp, one hospital and one outpatient clinic
were chosen as sentinel sites for surveillance. In Dadaab
refugee camp complex, Hagadera hospital and one
Hagadera health post were chosen as sentinel sites for
Dadaab because at the start of the project, they were the
busiest health facilities. In Kakuma, in addition to the
only hospital, one outpatient clinic was selected. The
two hospitals are the only facilities that offer inpatient
services for refugees in Kakuma and Hagadera, Dadaab.
They account for almost all hospitalisations.
Case definitions
At both sites we enrolled patients with influenza-like ill-
ness (ILI) and severe acute respiratory illness (SARI).
Definitions for ILI and SARI were adapted from those
of the WHO [26-28].
• ILI was defined as fever ≥ 38°C and cough or sore
throat.
• For children > 1 week and < 2 months old, SARI was
defined as an admission to the paediatric ward with any
of the following: respiratory rate > 60 per minute, severe
chest indrawing, nasal flaring, grunting, fever ≥ 38°C,
hypothermia < 35.5°C, or pulse oxygenation < 90%.
• For children 2 months to < 5 years of age, SARI was
defined as cough or difficulty breathing and any one of the
following: respiratory rate > 50/min for infants 2 months
to < 1 year old or > 40/min for children 1 to < 5 years old,
chest indrawing or stridor in a calm child, unable to drink
or breast feed, vomiting, convulsions, lethargic or uncon-
scious, or pulse oxygen saturation < 90%.
• For older children and adults ≥ 5 years of age, SARI
was defined as fever ≥ 38°C, and cough or sore throat,
and shortness of breath or difficulty breathing.
hospitalisation was a required part of the SARI case
definition in all ages. For every patient, surveillance offi-
cers recorded specific signs and symptoms so that case
classification could be validated. The maximum number
of eligible ILI patients was limited to the first three
cases per day for both sites.
Clinical specimens
Trained surveillance officers identified eligible patients,
administered a standardised questionnaire, and obtained
nasopharyngeal (NP) and oropharyngeal (OP) swab spe-
cimens for diagnostic testing. NP and OP swab speci-
mens were obtained according to the following
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procedure: a) a sterile nylon flocked plastic-shafted OP
swab (503CS01, Copan Diagnostics, Murrieta, CA, USA)
was used to rub the back of the oropharyngeal mucosal
membrane for 3-5 s and then placed into 1 mL of viral
transport media; b) a polyester-tipped flexible alumi-
nium-shafted NP swab was inserted into the nose until
it reached the nasopharynx, where it was rotated 180°
and left in place for 3-5 s. The swab was inserted into a
1-mL vial of viral transport media. The cryovials were
stored in a refrigerator at the health care facility and
kept at 2-8°C for up to 96 h; the vials were then shipped
to the Kenya Medical Research Institute (KEMRI)/CDC
laboratory in Nairobi. Transportation to and from
Dadaab and Kakuma is severely restricted; air transport
is not always guaranteed, and flights are regularly
diverted or cancelled with little or no notice. Consider-
ing their time-sensitivity, specimens were obtained only
if they could be shipped within 96 h of collection. For
two of the 3 years reported in this study, the NP and
OP specimens were inserted into the same vial and
tested as one specimen while in the final year the speci-
mens were placed in separate vials in which case a posi-
tive result from either specimen was sufficient to classify
a case as positive [29].
Specimen processing
Specimens were not tested if the following conditions
existed when the specimen arrived at the lab: the swab
was missing; the volume was less than 600 μL; the spe-
cimen was at room temperature; patient identification
was absent or incomplete; or the patient questionnaire
was absent. In addition, the test results were discarded
for any specimen whose human ribonuclease P (RNP)
gene (internal control) was negative. Testing for respira-
tory viruses was carried out by real-time reverse tran-
scriptase polymerase chain reaction (RT-PCR) at the
KEMRI/CDC laboratory. An aliquot of each respiratory
specimen was tested for influenza A and B viruses,
respiratory syncytial virus (RSV), adenovirus (AdV),
human parainfluenza viruses 1, 2 and 3 (PIV), and
human metapneumovirus (hMPV). Details of the proce-
dures used are described elsewhere [29-31].
Data collection, entry, and analysis
For every ILI and SARI case enrolled, a brief standardized
questionnaire was completed by staff at the health care
facility. Demographic information, medical information,
and a history of influenza vaccination were obtained
directly from adult patients and from the parent or guar-
dian for minors. Data were entered into a Microsoft
Access database (Microsoft Corporation, Washington,
USA) and analysed by SAS system for Windows, version
9.1 (SAS Institute Inc, Cary, North Carolina, USA) and
Microsoft Excel (Microsoft Corporation, Washington,
USA). Crude estimates of rates of hospitalisation per 1000
due to SARI for children < 5 years old were calculated by
dividing the number of SARI cases among children < 5
years old by the population of that age group in the camp.
Because the two hospitals are the only inpatient facilities
in the respective camps and account for almost all admis-
sions, we did not adjust for out-of-camp hospitalisation.
Monthly population data for Hagadera, Dadaab and
Kakuma camps for the months of September 2007 to
August 2010 were obtained from the UNHCR Health
Information System [32]. Population figures for Hagadera
for December 2008 were not available, so we estimated
the December 2008 population as the average of the
months of November 2008 and January 2009. The 95%
confidence intervals were calculated by using the Poisson
distribution [33,34]. Rates were also estimated for the < 1
year and 1- to < 5-year age groups and by location and
viral aetiology. When calculating these rates, Kenyan
nationals were not included in the numerator, because
population estimates for the local (non-refugee) popula-
tion were not known. We were interested in calculating
rates for acute onset illnesses; therefore, SARI cases with
symptom onset of > 14 days were excluded. Rates were
not calculated for children ≥ 5 years old and adults
because reliable denominator data was not available.
Ethical approval for the surveillance activities was
obtained from the KEMRI Ethical Review Committee
(SSC Protocol Number 1161). Institutional review was
waived by CDC because the study was considered to be
a non-research public health activity. Informed written
consent was obtained from all participants and from the
guardians of minors.
Results
During the study period, 6,647 patients meeting case
definitions for ILI and SARI were enrolled. Specimens
from 268 participants were discarded in the field before
shipment (shipment did not occur in time) and an addi-
tional 115 specimens were rejected by the laboratory
because of poor sample quality (see methods). Speci-
mens from 6,264 participants were tested: 3,323 (53.0%)
were from Kakuma and 2,941 (47.0%) were from
Dadaab; 3,394 (54.2%) were from males (Table 1). There
were 2,292 (36.6%) children < 1 year, 2846 (45.4%) 1-4
years, and 1,126 (18.0%) ≥ 5 years old. The median age
was 1 year (range: 1 month-84 years), and the median
number of days between symptom onset and enrolment
was 2 days (range: 0-38 days). A total of 6,179 (99.2%)
and 6,217 (99.8%) were enrolled within 7 days and 14
days of symptom onset, respectively. Date of symptom
onset was not recorded for 32 patients. Participants
were mainly refugees from Somalia (3,891 [62.1%]),
Sudan (1,441 [23.0%]), Ethiopia (183 [2.9%]), and from
other countries in east and central Africa (158 [2.5%]).
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Only 591 (9.4%) were Kenyan nationals receiving care at
the refugee health facilities (Table 1). No participant
had been vaccinated for influenza prior to being
enrolled and tested.
Of the 6,264 tested, illnesses for 4,449 (71.0%) were
classified as SARI and for 1,815 (29.0%) as ILI; 3,119
(49.8%) were positive for at least one virus (Table 1).
The numbers and proportions of specimens positive for
respiratory viruses were: AdV, 1361 (21.7%); RSV, 781
(12.5%); hMPV, 359(5.7%); PIV, 591 (9.4%); influenza A,
607 (9.7%); and influenza B, 161 (2.6%) (Table 1). Chil-
dren < 1 year old accounted for 47.0% of RSV-positive
patients, compared with 38.1% for AdV, 40.4% for
hMPV, 41.1% for PIV, 27.3% for influenza A, and 23.0%
influenza B (Figure 1). Table 1 below also shows propor-
tion positive for virus by refugee camp and by case
classification.
Rates of hospitalisation
The annual crude rate of SARI hospitalisation for 2007-
2010 was 57 per 1000 children < 5 years old per year
(Table 2). Virus-positive crude hospitalisation rates (per
1,000 children < 5 years old) were 14 for AdV, 9 for
RSV, 6 for PIV, 4 for hMPV, 5 for influenza A, and 1
for influenza B. The annual crude rate of SARI hospita-
lisation was highest in children < 1 year old (156 per
1000 children per year). Virus-positive hospitalisation
Table 1 Demographic distribution and viral prevalence in specimens tested, by camp, Kenya, September 2007-August
2010
Total (N = 6264)
n (%)
Location Case classification
Kakuma (N = 3323)
n (%)









Male 3394 (54.2) 1800 (54.2) 1594 (54.2) 939 (51.7) 2455 (55.2)
Female 2870 (45.8) 1523 (45.8) 1347 (45.8) 876 (48.3) 1994 (44.8)
Age
< 1 years 2292 (36.6) 1228 (37.0) 1064 (36.2) 520 (28.7) 1772 (39.8)
1 - < 2 years 1379 (22.0) 798 (24.0) 581 (19.8) 361 (19.9) 1018 (22.9)
2 - < 5 years 1467 (23.4) 815 (24.5) 652 (22.2) 497 (27.4) 970 (21.8)
≥ 5 years 1126 (18.0) 482 (14.5) 644 (21.9) 437 (24.1) 689 (15.5)
Nationality
Somali 3891 (62.1) 980 (29.5) 2911 (99.0) 996 (54.9) 2895 (65.1)
Sudanese 1441 (23.0) 1431 (43.1) 10 (0.3) 407 (22.4) 1034 (23.2)
Kenyan 591 (9.4) 578 (17.4) 13 (0.4) 315 (17.4) 276 (6.2)
Ethiopian 183 (2.9) 178 (5.4) 5 (0.2) 59 (3.6) 124 (2.8)
Other3 158 (2.5) 156 (4.7) 2 (0.1) 38 (2.1) 120 (2.7)
Infection prevalence
Adenovirus 1361 (21.7) 815 (24.5) 546 (18.6) 352 (19.4) 1009 (22.7)
RSV 781 (12.5) 364 (11.0) 417 (14.2) 155 (8.5) 626 (14.1)
hMPV 359 (5.7) 180 (5.4) 179 (6.1) 93 (5.1) 266 (6.0)
Parainfluenza 591 (9.4) 319 (9.6) 272 (9.3) 155 (8.5) 436 (9.8)
Influenza A 607 (9.7) 300 (9.0) 307 (10.4) 197 (10.9) 410 (9.2)
Influenza B 161 (2.6) 75 (2.3) 86 (2.9) 55 (3.0) 106 (2.4)
At least one virus 3119 (49.8) 1642 (49.4) 1477 (50.2) 837 (46.1) 2282 (51.3)
1Influenza-like illness; 2Severe acute respiratory infection; 3Burundi, Democratic Republic of Congo, Rwanda, Uganda
Figure 1 Virus isolation by age group from persons with
influenza-like illness or severe acute respiratory infection,
Kakuma and Dadaab refugee camps, Kenya, 2007-2010. Age
group distribution was < 1 year, n = 2292 (36.6%); 1- < 5 years, n =
2846 (45.4%); ≥ 5 years, n = 1126 (18.0%).
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crude rates per 1000 child-years for children < 1 year
old were 35 for AdV, 29 for RSV, 17 for PIV, 11 for
hMPV, 11 for influenza A, and 2 for influenza B. The
ratio of rates for children < 1 year and 1 to < 5 years
old was 3.7:1 for AdV, 5.5:1 for RSV, 4.4:1 for PIV, 5.1:1
for hMPV, 3.2:1 for influenza A, and 2.2:1 for influenza
B. The average crude SARI hospitalisation rates for chil-
dren < 5 years old were 1.6 times higher in Kakuma
than in Dadaab (p < 0.001). The rates for AdV and PIV
were 2.2 (p < 0.001) and 2.1 (p < 0.001) times higher for
Kakuma than for Dadaab. The 2009 pandemic influenza
A (pH1N1) was not associated with increased hospitali-
sation in either camp during the periods when pH1N1
was detected.
Seasonal distribution
In Dadaab, the rates for most viruses peaked from
November to February (Figure 2). The rates of RSV-
associated hospitalisation were highest during that time,
with a minor increase in June. The rates for hMPV and
influenza A peaked in November and December (Figure
3). PIV was mostly detected in January and February,
and no distinct seasonal pattern was seen for AdV (Fig-
ure 3). In Kakuma, no distinct seasonality patterns were
observed.
Discussion and conclusions
Our study suggests that viruses are a major cause of sig-
nificant respiratory infections in two large refugee
camps in Kenya; at least one virus was detected in speci-
mens from 50% of the participants. Although data from
UNHCR’s Health Information System suggest that ARI
is the highest cause of morbidity and mortality in the
refugee camps, this is the first study that we are aware
of to demonstrate the viral aetiologies of these infec-
tions. AdV and RSV were the leading pathogens identi-
fied, accounting for approximately two-thirds of viruses
detected. As expected, rates associated with viral
infection were highest for children < 12 months of age
[4,6,35,36]. The crude rates of hospitalisation per 1000
for SARI were more than four times higher for children
< 1 compared to children 1 to < 5 years old.
Our findings for these two sites were similar to those
reported from non-refugee populations in Mozambique,
Gambia, Nigeria, South Africa, Indonesia, and India
[37-39]. Rates per 1000 for severe infections due to RSV
for children < 1 year and < 5 years of age were reported
to be 15 and 9 (South Africa), 15 and 5 (Mozambique),
and 16 and 10 (Indonesia) [39]. In a 3-year cohort study
in rural India, severe lower respiratory tract infection
(LRTI) rates per 1000 due to RSV for children aged < 1,
1-2 years, and 2-3 years were found to be 14, 7, and 0
respectively [37]. In a meta-analysis of incidence of RSV
associated severe LRTI in developing countries, Nair et
al. estimated incidence in the < 1 year age group per
1000 per year as 22 (95% CI 9-53) [40]. Rates of respira-
tory virus infection in children < 5-years-old in the two
















Kakuma < 1 yr 52.2 (41.7 - 65.4) 32.1 (24.1 - 42.8) 9.7 (5.7 - 16.3) 25.0 (18.1 - 34.7) 12.3 (7.7 - 19.5) 1.2 (0.3 - 5.3) 188.0 (167.0 - 211.7)
1 to 5 yrs 13.8 (11.3 - 16.9) 6.1 (4.5 - 8.2) 3.1 (2.0 - 4.7) 5.4 (3.9 - 7.5) 4.2 (2.9 - 6.1) 1.4 (0.8 - 2.7) 49.8 (44.8 - 55.4)
< 5 yrs 20.6 (17.7 - 23.9) 10.7 (8.6-13.1) 4.2 (3.0-5.9) 8.9 (7.0-11.1) 5.6 (4.2 - 7.5) 1.4 (0.8 - 2.5) 74.2 (68.5 - 80.3)
Dadaab < 1 yr 23.5 (17.8 - 30.9) 26.8 (20.7 - 34.7) 11.4 (7.7 - 17.0) 11.3 (7.6 - 16.8) 10.3 (6.8 - 15.6) 2.9 (1.3 - 6.3) 134.3 (119.7 - 150.6)
1 to 5 yrs 6.6 (5.2 - 8.3) 4.7 (3.6 - 6.2) 1.5 (0.9 - 2.4) 2.8 (2.0 - 4.1) 2.9 (2.1 - 4.2) 0.7 (0.3 - 1.4) 28.4 (25.4 - 31.8)
< 5 yrs 9.5 (7.9 - 11.3) 8.5 (7.0 - 10.3) 3.2 (2.3 - 4.3) 4.3 (3.3 - 5.6) 4.2 (3.2 - 5.5) 1.1 (0.6 - 1.8) 46.5 (42.9 - 50.4)
Overall < 1 yr 35.0 (29.4 - 41.7) 29.0 (23.9 - 35.1) 10.7 (7.8 - 14.7) 16.8 (13.1 - 21.6) 11.1 (8.2 - 15.1) 2.2 (1.1 - 4.4) 155.9 (143.5 - 169.3)
1 to 5 yrs 9.4 (8.1 - 11.0) 5.2 (4.3 - 6.4) 2.1 (1.5 - 2.9) 3.9 (3.0 - 4.9) 3.4 (2.7 - 4.4) 1.0 (0.6 - 1.6) 36.8 (34.1 - 39.8)
< 5 yrs 13.8 (12.3 - 15.5) 9.3 (8.1 - 10.8) 3.6 (2.9 - 4.5) 6.1 (5.1 - 7.3) 4.8 (3.9 - 5.8) 1.2 (0.8 - 1.8) 57.4 (54.3 - 60.8)
195% confidence Interval
Figure 2 Proportion of specimens positive for at least one
virus among children < 5 years old with severe acute
respiratory infection, Dadaab and Kakuma Refugee Camps,
Kenya, September 2007 to August 2010.
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camps were ~2 times those reported for the United
States or Europe but were similar to rates found in spe-
cial populations groups within these countries [4,41,42].
For instance, in the United States, rates of hospitalisa-
tion for respiratory infections were found to be up to 5
times higher among Alaskan Native people than the US
average [43].
The surveillance period overlapped with the 2009 pan-
demic influenza A (H1N1). While 2009 pH1N1 virus
became the predominant circulating influenza A virus
subtype, it was not associated with unusual rates in hos-
pitalisation among the refugee population.
This study adds to our knowledge of the seasonal varia-
tions of respiratory viral infections in Africa. Even though
both sites have very similar climatic conditions (arid and
dry), we found remarkable differences in seasonal variation
of ARI and specific virus activity, which might indicate
varied transmission patterns in different subregions of the
continent. There was distinct seasonality in Dadaab, with
peak transmission occurring in November and December.
Kakuma, on the other hand, despite having up to 60%
more hospitalisation due to SARI, had no such seasonality.
These differences may be due to the locations of the two
camps. Kakuma, in the northwest of the country near the
Ugandan and Sudanese borders, may reflect trends of viral
transmission in the broader equatorial regions of central
Africa, while Dadaab, located in the east near the Somali
border, may reflect trends of transmission in the horn of
Africa. Similar differences in seasonality between neigh-
bouring tropical countries in Africa and Asia have been
reported previously [39,44]. Additional surveillance points
are required to further evaluate temporal variations of ARI
due to viral illness.
Refugee populations are especially at risk for severe ill-
ness from respiratory infections [12,20,21]. Unique chal-
lenges make individuals residing in camp settings
especially vulnerable to exposure to airborne diseases.
The camp system of registration, food, water, and fire-
wood distribution encourages crowding of large groups
in small, confined spaces. In addition, malnutrition, high
population density and poor shelter conditions may con-
tribute to the elevated rates seen in this population. The
availability of new, sensitive, reliable, and cost-effective
technologies that can test multiple pathogens simulta-
neously from one easily obtainable specimen means that
surveillance systems can now be set up for previously
inaccessible populations [45].
Our study has several limitations: 1) Not all eligible
individuals meeting the case definitions were identified,
and not all those who were identified agreed to partici-
pate in the study. Thus the actual rates of SARI and virus
infection associated SARI is likely higher than reported.
2) We did not attempt to collect data on all cases of ILI
in the camp; therefore, we were not able to estimate rates
of ILI. 3) Although the two hospitals are the only ones in
the camps, refugees may have sought health care else-
where; we did not capture information on health utiliza-
tion among the refugees. If refugees did seek treatment
elsewhere, our rates would again underestimate the
actual rates. 4) The results of this study should also be
interpreted with caution especially for pathogens e.g.
AdV with known background carriage in healthy, asymp-
tomatic individuals. Finally, the surveillance system was
not designed to measure all indicators of ARI disease;
due to lack of data, we could not estimate key outcomes,
including mortality and duration of hospitalisation.
Figure 3 Proportion of specimens positive for adenovirus, respiratory syncytial virus (RSV), parainfluenza viruses (PIV), human
metapneuomovirus (hMPV), influenza A, and influenza B among children < 5 years old with severe acute respiratory infection in
Dadaab refugee camp, Kenya, September 2007 to August 2010.
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Our study found that viruses are a major cause of
respiratory infection in the two refugee camps. To
decrease the burden of respiratory illnesses requires a
multipronged interventional plan. Physical interventions
like handwashing with soap have been found to decrease
the odds of respiratory infection by as much 55%, and
nosocomial transmission has been shown to decrease by
66% when cohort nursing and wearing of gloves and
gowns were introduced [46-48]. Measures could be put
in place to minimise crowding, which is very common
in refugee camps and has been associated with increased
transmission of respiratory infections, and to target pub-
lic health education messages during peak transmission
months [49]. All SARI cases in this study were hospita-
lised in a ward shared by severely sick children present-
ing with other conditions. While we have not explored
hospital acquired infection in this study, measures could
also be taken to minimise potential nosocomial trans-
mission. Because of the high rates of morbidity asso-
ciated with these viruses in the refugee population, in
addition to the implementation of innovative and effec-
tive approaches to achieve sustained compliance with
hand hygiene promotions, refugees should be prioritised
for vaccines when they become available [10,16-18] ARI
prevention and control in refugee populations should be
a key priority area for UNHCR, its partner agencies, and
the international community.
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